Construction Begins for Clinical Translational Science Building

CTSB rendering

Across the country, translational research took center stage in 2009 – and Rochester was ahead of many of its peers in establishing a central hub of resources, networks and expertise to push innovative, basic science toward patients faster than ever. Indeed, when Congress authorized the NIH in 2006 to fund a series of large translational research grants, URMC was among the first in line. Years of planning and creative, collaborative thinking led to our success in securing funding, and the same high level of creativity will drive the CTSB project in the future.

In another testament to our resiliency, several key initiatives moved forward in 2009 despite the loss of CTSI principal investigator David Guzick, M.D., Ph.D., who left Rochester to join the University of Florida.

  • Construction began in the summer of 2009 on the $76 million building, which is located on the south side of the Medical Center campus, next to the School of Nursing, along Crittenden Boulevard. With $50 million in support from New York State, the CTSB is expected to be completed in 2011.
  • The CTSI established two new research centers that straddle many departments and disciplines, led by renowned neurologist Karl Kieburtz, M.D., M.P.H., and public health expert Nancy Bennett, M.D. Kieburtz will head the Center for Human Experimental Therapeutics, focusing on initial human investigation and proof of mechanism/concept. He is a professor of Neurology, Environmental Medicine, and of Public Health Sciences. Bennett and co-investigator Geoffrey Williams, M.D., Ph.D., are operating the Healthy Living Center, a collaboration between the CTSI, the Center for Community Health, and a regional network of practicing clinicians. She is director of the URMC Center for Community Health, and deputy director of the Monroe County Department of Public Health.
  • The CTSI has funded 60 pilot research projects to scientists throughout the Medical Center. All have direct relevance to patients, such as an investigation into the metabolic pathways and novel lipids involved in heart disease and cancer, and the influence of high-dose omega-3 fatty acids and aspirin on lipids.
  • URMC’s CTSI joined a national effort to develop an easy tool that links researchers and volunteers interested in participating in research studies. ResearchMatch is a part of a not-for-profit venture that uses a secure and convenient web portal. URMC is one of 39 CTSI-funded institutions participating in the program, which was developed by Vanderbilt University;.